Oramed Pharmaceuticals (ORMP) Proxy filing summary

Executive summary

• The annual meeting is scheduled for September 15, 2026, in Jerusalem, with six director nominees up for election and several key proposals on the agenda.

• Shareholders can vote online, by phone, mail, or in person, with a record date of July 20, 2026, and 41,597,354 shares eligible to vote.

• The Board recommends voting in favor of all proposals, including director elections, auditor ratification, incentive plan amendment, say-on-pay, and adjournment.

Voting matters and shareholder proposals

• Proposals include election of six directors, ratification of Kesselman & Kesselman as auditor, amendment to increase shares under the incentive plan, advisory say-on-pay, advisory say-on-frequency, and adjournment if needed.

• Board recommends “FOR” all proposals and “EVERY THREE YEARS” for say-on-frequency.

• Shareholders may submit future proposals for the 2027 meeting by following specified deadlines and procedures.

Board of directors and corporate governance

• Board consists of six members, with four deemed independent under Nasdaq rules.

• Directors serve one-year terms; nominees include Nadav Kidron, Dr. Miriam Kidron, Dr. Arie Mayer, Yehuda Reznick, Benjamin Shapiro, and Dr. Daniel Aghion.

• Committees include Audit, Compensation, Investment, and Nominating, all composed of independent directors.

• Annual board and committee evaluations are conducted for continuous improvement.

• Code of Ethics and insider trading policy are in place for directors, officers, and employees.